You can buy Lucivora at the lowest price in the online pharmacy Nextgen.ooo . Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor. It works by suppressing the levels of D-2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH1 and IDH2 isoforms. Vorasidenib displayed improved brain penetration and higher drug exposure compared to other IDH inhibitors such as ivosidenib and enasidenib. Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.
 
Vorasidenib works to reduce tumour growth and invasion in IDH-mutant glioma. In patients with low-grade IDH-mutant glioma, vorasidenib significantly improved progression-free survival and delayed the time to the next anticancer intervention.Mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes can be identified in various malignancies, including acute myeloid leukemia (AML) and gliomas. Mutant enzymes produce an oncometabolite D-2-hydroxyglutarate (2-HG), which contributes to oncogenesis and tumour growth by blocking the activity of α-ketoglutarate–dependent enzymes and causing epigenetic dysregulation, such as global DNA hypermethylation, and interfering with immunity.
 
Efficacy was evaluated in 331 participants with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or isocitrate dehydrogenase-2 mutation following surgery enrolled in INDIGO (NCT04164901), a randomized, multicenter, double-blind, placebo-controlled trial. Participants were randomized 1:1 to receive vorasidenib 40 mg orally once daily or placebo orally once daily until disease progression or unacceptable toxicity. In summary, with 6 months of additional follow-up, vorasidenib showed robust efficacy, with greater magnitude of progression free survival and a reduction in tumor volume than placebo.